Compare KZIA & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KZIA | DAVA |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | Australia | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.5M | 159.1M |
| IPO Year | 2002 | 2015 |
| Metric | KZIA | DAVA |
|---|---|---|
| Price | $14.38 | $3.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $19.50 | $13.50 |
| AVG Volume (30 Days) | 204.2K | ★ 242.2K |
| Earning Date | 06-04-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.07 |
| P/E Ratio | ★ N/A | $20.02 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $2.55 |
| 52 Week High | $17.40 | $14.99 |
| Indicator | KZIA | DAVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 53.64 |
| Support Level | $11.39 | $2.64 |
| Resistance Level | $14.75 | $3.24 |
| Average True Range (ATR) | 1.05 | 0.15 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 90.77 | 63.89 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.